JNJ vs ABBV — Key Metrics

Metric JNJ (JOHNSON & JOHNSON) ABBV (ABBVIE INC)
Price272.7286.01
Market Cap656.47 Billion505.56 Billion
P/E (TTM)40.8249.06
P/B (Quarterly)7.611-109.235
P/S (TTM)6.617.66
Net Profit Margin (TTM)16.215.7
Gross Margin (TTM)67.673.7
ROE (TTM)19.6-201.0
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

JOHNSON & JOHNSON
vs
 
ABBVIE INC
 
JOHNSON & JOHNSON
vs
 
ABBVIE INC
Performance Comparison
AI Model Recommendation
JNJ · JOHNSON & JOHNSON

Outperform

21
UnderperformOutperform
ABBV · ABBVIE INC

Outperform

44
UnderperformOutperform
Recommendation Summary

Both stocks are projected to outperform the market over the next year. If you have to make a choice, Upfront Recommendation: ABBV.

Financial Metrics
Prices delayed ~15 min
JNJ Metrics ABBV
$272.70 Price $286.01
— Market Capitalization —
40.82 Price to Earnings Ratio 49.06
6.61 Price to Sales 7.66
31.88 Price to FCF Ratio 26.79
9.78 Price to Gross Profit 10.39
40.82 Price to R&D 50.75
11.65 Price to Current Assets 13.49

JNJ vs ABBV at a glance

Johnson & Johnson (JNJ) and Abbvie INC (ABBV) are both Drug Manufacturers - General companies in the Healthcare sector. JNJ is the larger, at $656.5 billion in market value against $505.6 billion for ABBV, about 1.3 times the size.

On trailing-twelve-month figures, JNJ trades at 40.8 times trailing earnings and ABBV at 49.1; net profit margins are 16.2% and 15.7%.

The Upfront Investment model currently rates both Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.